ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1848	National Cancer Institute	Html	es	Tratamiento del cáncer de piel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de piel.	Compton CC 0.427006 ángulo nariz-mejilla 0.312075 Cutaneous squamous 0.410175 criocirugía frente 0.310658 skin cancers 0.337834 señalización tipo erizo 0.316126 basal-cell carcinoma 0.31436 American Cancer Society 0.31065 Casciato DA 0.3104 7th ed 0.425796 Dermatol Surg Oncol 0.322688 TFD frente 0.31135 cutaneous carcinomas 0.448478 Mohs surgery is 0.310939 Plast Reconstr Surg 0.318551 carcinomas cutáneos 0.316845 Estados Unidos 0.319384 Natl Cancer Inst 0.311163 human papillomavirus infection 0.320874 CCE invasor 0.312649 Euros frente 0.310849 N2a Metástasis 0.310265 cell carcinomas 0.926899 escisión frente 0.315633 Arch Dermatol 0.342458	Carcinoma apocrino 0.319357 uncomplicated basal cell 0.313087 Invest Dermatol 0.31893 Mohs micrographic surgery 0.311178 micosis fungoide 0.313548 Cancer Staging Manual 0.594205 recidivas locales 0.316877 PDQ Tratamiento 0.321192 New York 0.409746 Day CL Jr 0.315276 clasificación tnm 0.310941 células escamosas cutáneos 0.311636 Dermatol Surg 0.324225 Byrd DR 0.419056 T2b Tumor 0.314992 Karagas MR 0.311264 basal cell carcinomas 0.750035 American Joint Committee 0.344157 párpadoa aReproducción 0.326393 tumor fotosensibilizadores 0.313881 Tis Carcinoma 0.334823 Carcinoma arising 0.318249 AJCC Cancer Staging 0.604512 Edge SB 0.427178	CLICK HERE
1878	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) masculino (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) masculino.	Giordano SH 0.546628 Italian Oncology Group 0.503266 aromatase inhibitors 0.504835 Sin embargo 0.505052 accessed october 0.502081 American Cancer Society 0.521913 sumario tratamiento 0.50893 PALB2 mutations 0.502161 Terapia sistémica preoperatoria 0.504717 Instituto Nacional 0.507139 Vlamis V 0.505558 male breast 0.773618 DeVita VT Jr 0.502939 Wong GY 0.505822 population-based study 0.506079 carcinoma lobulillar 0.502812 hereditary male breast 0.514858 estadificación tnm 0.502579 Buzdar AU 0.511225 breast carcinoma 0.529746 German Breast Group 0.523976 Adjuvant therapy with 0.503518 male breast carcinoma 0.523697 Cancer Facts 0.511201 parientes mujeres 0.50281	tumores pten 0.506695 Cancer Res Treat 0.581998 National Cancer Institute 0.509524 or without gonadotropin-releasing 0.502999 PDQ Tratamiento 0.571327 versus ia 0.508803 Hortobagyi GN 0.519998 Intern Med 0.505973 cancer susceptibility 0.510328 cases from 0.502419 metastatic breast 0.510618 Clin Oncol 0.505305 IA vs 0.504284 Physician Data Query 0.502682 breast cancer 0.966614 estadios tnm 0.502728 Oncology Group Phase 0.503374 Aromatase inhibitors with 0.503642 PDQ Sofocos 0.507587 Current management 0.505493 Oncology Group 0.504752 Borgen PI 0.505535 Hormonal treatment 0.502423 Breast Cancer Res 0.608904	CLICK HERE
1915	National Cancer Institute	Html	es	Tratamiento del cáncer de intestino delgado (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de intestino delgado.	PDQ Tratamiento 0.7 múltiples ocasiones 0.771101 siguientes procedimientos 0.819416 presente sección 0.734818 tubo gi 0.768209 Physician Data Query 0.747544 siguientes tipos 0.756902 libre uso 0.701583 rayos x 0.762021	Serie GI 0.757795 siguientes enlaces 0.717853 siguientes riesgos 0.701351 tumores carcinoides 0.993734 siguientes sumarios 0.858967 siguientes pruebas 0.800933 alto contenido 0.777945 Instituto Nacional 0.793857	CLICK HERE
2012	National Cancer Institute	Html	es	Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón.	PDQ Exámenes 0.778524 Physician Data Query 0.91448 mayores probabilidades 0.586703 Estados Unidos 0.865536 rayos x 0.605899 prevención revisa 0.573952 PDQ Prevención 0.807908 siguientes exámenes 0.801099 principal causa 0.623129	información ayuda 0.574441 vías respiratorias 0.622976 National Cancer Institute 0.606892 siguientes riesgos 0.571899 PDQ Aspectos 0.723454 siguientes sumarios 0.714394 Lung Screening Trial 0.688089 Instituto Nacional 0.689164	CLICK HERE
2018	National Cancer Institute	Html	es	Prevención del cáncer de pulmón (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	agentes carcinógenos 0.462163 factores alimentarios 0.825457 Retinol Efficacy Trial 0.359125 Cancer Research Fund 0.363502 how much 0.341238 Pinsky PF 0.34171 Sin embargo 0.481037 largo plazo 0.406049 tasas anuales promedio 0.375764 Health Care Policy 0.356657 PDQ Consumo 0.41794 vitaminas antioxidantes e 0.352553 vitamina e 0.340093 Outcomes Prevention Evaluation 0.355777 estudio atbc 0.383777 Estados Unidos 0.918409 Natl Cancer Inst 0.379434 Surgeon General Report 0.371012 bajo contenido 0.394946 numerosos estudios 0.665863 Women’s Health Study 0.359964 principal factor 0.344815 verdadera relación causa-efecto 0.391629 Beta-Carotene Cancer Prevention 0.361998 altas concentraciones 0.445954	childhood cancer 0.413412 radón causa 0.381229 hombres finlandeses fumadores 0.435889 Multi-Ethnic Cohort Study 0.379617 Subsequent neoplasms 0.341756 tabaco causa 0.392636 alta prevalencia 0.370255 múltiples lesiones 0.390734 elementos carcinógenos 0.375898 Health Study 0.393239 actividad física protegen 0.368641 Data Monitoring Committee 0.35531 Heart Protection Study 0.358634 paciente fumador 0.3962 antecedentes familiares 0.486318 Cancer Prevention Study 0.381093 gas radón 0.368394 principal causa 0.345807 pacientes fumadores 0.416554 Cancer Survivor Study 0.382901 múltiples lesiones premalignas 0.362501 mayores incrementos 0.341189 Cancer Prevention 0.39737 HOPE-The Ongoing Outcomes 0.356111	CLICK HERE
2116	National Cancer Institute	Html	es	Exámenes de detección del cáncer de testículo (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo.	accessed july 0.160067 Task Force reaffirmation 0.216432 Walsh TJ 0.2486 accessed october 0.163022 American Cancer Society 0.870604 nonseminomatous testicular tumors 0.345536 Preventive Services Task 0.945486 Pichlmeier U 0.270713 Instituto Nacional 0.34053 benign testicular neoplasms 0.344213 risk factors 0.483284 Genitourinary Cancer 0.306221 PDQ Exámenes 0.341146 population-based study 0.15915 Estados Unidos 0.241886 Natl Cancer Inst 0.349819 Clinical epidemiology 0.161836 Testicular carcinoma 0.320625 Database Syst Rev 0.192348 Catalona WJ 0.154934 SEER Cancer Statistics 0.334649 germ cell neoplasms 0.219944 Testicular germ-cell 0.296343 testicular intraepithelial neoplasia 0.348844 cohort study 0.156662	Cancer Facts 0.319251 Nat Rev Urol 0.202726 Hotaling JM 0.155392 National Cancer Institute 0.62099 environmental risk factors 0.226796 Martinus Nijhoff 0.158009 potencial metastásico 0.160038 PDQ Tratamiento 0.296251 riesgo promedio 0.189608 Misso ML 0.156367 Intern Med 0.429314 Cochrane Collaboration 0.160947 saco vitelino 0.164571 Clin Oncol 0.159643 Physician Data Query 0.188901 Services Task Force 0.942129 hombres morirán 0.216745 Arch Intern Med 0.217716 Schonfeld SJ 0.155751 germ cell tumors 0.429551 hombres jóvenes 0.207617 Male infertility 0.157895 Sigurdson AJ 0.156081 características histológicas benignas 0.192503	CLICK HERE
3437	National Cancer Institute	Html	es	Prevención del cáncer de estómago (gástrico) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de estómago y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	siguientes factores 0.837019 voluntarios sanos 0.649737 Physician Data Query 0.828425 siguientes afecciones 0.700348 Estados Unidos 0.992286 suficiente ejercicio 0.665482 prevención revisa 0.656327 PDQ Prevención 0.701412 bacteria helicobacter 0.66365	National Cancer Institute 0.659684 vitamina c 0.655742 tipo a 0.654153 siguientes riesgos 0.647812 alto contenido 0.74292 siguientes sumarios 0.735961 vitamina b12 0.670397 Instituto Nacional 0.708301	CLICK HERE
3561	National Cancer Institute	Html	en	Obesity	People who are obese may have an increased risk of several types of cancer, whereas eating a healthy diet, being physically active, and keeping a healthy weight may help reduce risk of some cancers.	National Heart 0.499901 Obesity 0.347906 healthy diet 0.745052 gallbladder 0.258317 healthy behaviors 0.755955 Cancer fact sheets 0.830969 healthy weight 0.977177 Physical Activity 0.512739 Overweight 0.225819 Blood Institute 0.497718 kidney 0.214739	uterus 0.266957 menopause 0.223953 high blood pressure 0.86289 heart disease 0.510853 pancreas 0.241431 cancers 0.402713 colon 0.229687 risk 0.325352 rectum 0.279116 information 0.236001	CLICK HERE
16847	National Cancer Institute	Html	en	Safety of Nanotechnology Cancer Treatment	Nanotechnology is a powerful tool for combating cancer. NCI's Alliance for Nanotechnology in Cancer is continuously testing the safety of this new technology.	nanotech applications 0.677357 animal models 0.640611 new technology 0.654112 tissue damage 0.64104 cancer therapy 0.659011 ambient incidental nanoparticles 0.981236 high reactivity 0.657801 energy consumption 0.667996 volcanic ash 0.655357 small size 0.652566 nanomaterial safety 0.671123 NCL works 0.785834 greenhouse gas emissions 0.807194 nanomaterials 0.638465 potential health risks 0.757642 potential toxicity 0.657709 industrial applications—have 0.651915 voluntary-consensus standards 0.640352 powerful tool 0.664491 physicochemical properties 0.648003 available data 0.647533 NCL 0.841511 NCL tests 0.795621 unresolved debate 0.653791 unique tensile 0.653407	specific type 0.6502 over-the-counter dandruff remedies 0.781003 drug carriers 0.640153 potential risks 0.643319 Nanotechnology Characterization Laboratory 0.835959 different nanoparticles 0.793593 NCI Alliance 0.651255 order-of-magnitude higher levels 0.778354 nanoparticle exposure studies 0.785887 intramural program 0.646486 background incidental nanoparticles 0.982807 Stone Age 0.656862 nanomaterial—carbon nanotubes 0.650728 cancer applications 0.701263 human activities 0.656976 household cleaning products 0.76545 sea spray 0.653365 animal studies 0.647308 cancer research communities 0.992223 toxicity testing 0.646545 nanomaterial types 0.658682 medical applications 0.642559 magnetic properties 0.653737 family pets 0.646993	CLICK HERE
17186	National Cancer Institute	Html	en	TMIST (Tomosynthesis Mammographic Imaging Screening Trial)	TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).	routine screening mammogram 0.506393 entire study group 0.421549 tomosynthesis mammography 0.449515 health plans 0.41281 3-D mammography 0.660743 trial 0.465454 breast cancer status 0.514295 standard digital mammography 0.512193 3-D mammogram 0.462356 women ages 0.504522 following factors 0.42666 breast biopsies 0.439927 fewer false-positive test 0.416422 researchers 0.394009 2-D screening mammograms 0.502737 mammography clinics 0.435449 aggressive breast cancers 0.493477 ECOG-ACRIN Cancer Research 0.42875 2-D mammography 0.505053 3-D mammograms 0.447984 hormone replacement therapy 0.765582 randomized breast 0.472367 personal risk factors 0.42803 primary care doctors 0.417168 women 0.662197	risk changes 0.412147 fewer harder-to-treat cancers 0.422139 study 0.460399 best ways 0.450667 mammograms 0.529145 age group 0.430585 certain groups 0.456471 breast cancers 0.534289 dense breasts 0.527755 complete cost 0.412269 premenopausal women 0.386263 routine mammogram 0.443785 mammogram 0.569066 3-D mammography machines 0.510266 3-D mammography images 0.549905 breast cancer screening 0.609852 newly diagnosed breast 0.491574 nearby lymph node 0.415404 breast cancer 0.940336 trial record 0.381013 tissue samples 0.430822 genetic changes 0.428717 Women’s health 0.38389 family history 0.510755	CLICK HERE